

# Differential Regulation of Native Estrogen Receptor-Regulatory Elements by Estradiol, Tamoxifen, and Raloxifene

Nitzan Levy, Dierdre Tatomer, Candice B. Herber, Xiaoyue Zhao, Hui Tang, Toby Sargeant, Lonelle J. Ball, Jonathan Summers, Terence P. Speed, and Dale C. Leitman

*Departments of Obstetrics, Gynecology, and Reproductive Sciences and Center for Reproductive Sciences, Cellular and Molecular Pharmacology (N.L., D.T., C.B.H., L.J.B., J.S., D.C.L.), University of California, San Francisco, California 94143; Departments of Nutritional Sciences and Toxicology (D.C.L.) and Statistics (X.Z., H.T., T.P.S.), University of California, Berkeley, California 94720; and Division of Genetics and Bioinformatics, The Walter and Eliza Hall Institute of Medical Research (T.S., T.P.S.), Parkville, Victoria 3052, Australia*

**Estrogen receptors (ERs) regulate gene transcription by interacting with regulatory elements. Most information regarding how ER activates genes has come from studies using a small set of target genes or simple consensus sequences such as estrogen response element, activator protein 1, and Sp1 elements. However, these elements cannot explain the differences in gene regulation patterns and clinical effects observed with estradiol (E<sub>2</sub>) and selective estrogen receptor modulators. To obtain a greater understanding of how E<sub>2</sub> and selective estrogen receptor modulators differentially regulate genes, it is necessary to investigate their action on a more comprehensive set of native regulatory elements derived from ER target genes. Here we used chromatin immunoprecipitation-cloning and sequencing to isolate 173 regulatory elements associated with ER $\alpha$ . Most elements were found in the introns (38%) and regions greater**

**than 10 kb upstream of the transcription initiation site (38%); 24% of the elements were found in the proximal promoter region (<10 kb). Only 11% of the elements contained a classical estrogen response element; 23% of the elements did not have any known response elements, including one derived from the naked cuticle homolog gene, which was associated with the recruitment of p160 coactivators. Transfection studies found that 80% of the 173 elements were regulated by E<sub>2</sub>, raloxifene, or tamoxifen with ER $\alpha$  or ER $\beta$ . Tamoxifen was more effective than raloxifene at activating the elements with ER $\alpha$ , whereas raloxifene was superior with ER $\beta$ . Our findings demonstrate that E<sub>2</sub>, tamoxifen, and raloxifene differentially regulate native ER-regulatory elements isolated by chromatin immunoprecipitation with ER $\alpha$  and ER $\beta$ . (*Molecular Endocrinology* 22: 287–303, 2008)**

**D**RUGS THAT INTERACT with estrogen receptors (ERs) are commonly used to treat numerous reproductive conditions. Estrogens are mainly used for contraception and to treat a variety of menopausal symptoms, such as hot flashes and urogenital atrophy. However, the use of estrogens for menopausal

symptoms has been severely curtailed after the results of the Women's Health Initiative trial found that the risks of hormone therapy exceed the benefits (1). The selective estrogen receptor modulators (SERMs) differ from estrogens in that they exhibit both agonistic and antagonistic properties. Tamoxifen is the prototypic SERM that acts as an antagonist in the breast and an agonist in bone and uterus (2). Therefore, tamoxifen is used to treat and prevent ER-positive breast tumors (3). Raloxifene behaves similarly to tamoxifen in the breast and bone (4, 5) but does not elicit an agonistic action in the uterus (6). Raloxifene is hence approved for the prevention and treatment of osteoporosis. Although the SERMs have some exciting properties, a major limitation is that they do not prevent hot flashes. Furthermore, the results of clinical trials with SERMs are showing that both drugs can produce serious adverse effects (7). These observations clearly indicate that it is essential to develop a new generation of safer drugs that target ERs. To achieve this goal, a greater understanding of how estrogens and SERMs regulate genes that mediate their beneficial and adverse effects is needed.

## First Published Online October 25, 2007

Abbreviations: AF, Activation function; AP-1, activator protein 1; *CECR6*, Cat eye syndrome chromosome region candidate 6; ChIP, chromatin immunoprecipitation; ChIP-CS, ChIP-cloning and sequencing; E<sub>2</sub>, estradiol; ER, estrogen receptor; ERE, estrogen response element; *H19*, imprinted maternally expressed untranslated mRNA; NF $\kappa$ B, nuclear factor- $\kappa$ B; *LLGL2*, lethal giant larvae homolog 2; *NKD*, naked cuticle homolog; *NKG2*, killer cell lectin-like receptor subfamily C; *NKG2E*, killer cell lectin-like receptor; qPCR, quantitative real-time PCR; SERM, selective estrogen receptor modulator; *SPAT13*, spermatogenesis associated 13; SRC, steroid receptor coactivator; tk, thymidine kinase; TSS, transcription start site.

***Molecular Endocrinology* is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.**

**Table 1.** ER $\alpha$  Binding Sites Located in Introns of Target Genes

Gene Description	Location	Accession No.	ERE	AP-1	SP1	NF $\kappa$ B	FOXA1	Gene Description	Location	Accession No.	ERE	AP-1	SP1	NF $\kappa$ B	FOXA1
DnaI (Hsp40) homolog, subfamily C, member 6	19284	AB007942						Adaptor-related protein complex 3 $\delta$ 1 subunit	2933	AC006545					
Protein tyrosine phosphatase, receptor type, M <sup>b</sup>	376229	BC040543						Astrofascin	133783	AB006627					
Cytoplasmic polyadenylation element bp 4	29026	AB051460						NY-REN-41 antigen	1650	AF155108					+
Similar to keratin, type I cytoskeletal 18	3550	XM_497554			+			Lipase, hepatic <sup>a</sup>	21702	AF037404		+			+
Protocadherin 11 X-linked	348316	AB026187	+	+	+			FLJ42117 protein	43282	AK124111				+	
Solute carrier, seven thrombospondin repeats	217329	AC004615						Fibroblast growth factor 12	11760	AK125307		+			
Sema carrier family 37 member 2	435	AK074100						Chromosome 10 open reading frame 112	226328	AL590378					
Phosphodiesterase 4B <sup>a</sup>	143115	BC036108		+				Putative nuclear protein ORF1-FL49	17774	AJ245877		+			+
CUB and Sushi multiple domains 1	779937	A4889055				+		Glutamate receptor, ionotropic, kainate 4	19998	S67803					
Calcium channel L type, $\alpha$ 1B subunit	74357	M84172			+			Inhibitor of $\kappa$ light polypeptide gene enhancer	5571	AF062089		+			
RNA-binding motif single-stranded interacting protein	3451	AF023259		+	+			Chromosome 14 open reading frame 171	31955	AC007375					
Amnortrophic lateral sclerosis 2	346514	AB053321		+				Protein tyrosine phosphatase receptor type f	43512	BC034046					+
Cat eye syndrome chromosome region candidate 6	10	AF307451		+	+		+	Chromosome 20 open reading frame 44	12409	AF173883					
Solute carrier family 19 member 1	9602	AF004354	+				+	Hypothetical protein LOC285692	586	BC031253					
TNFR receptor member 19	34535	BC047321						Adenosine deaminase, RNA-specific, B1	29950	AF001042					+
Ryanodine receptor 3	75898	AB001025						Plasminogen-like	1645	AK124365			+		+
Hypothetical protein FLJ30707	8470	AK055269						Similar to ankyrin repeat domain 30A	29389	XM_291770			+		+
(3)mbt-like 2	3653	AJ305226			+			Rab6-interacting protein 2	68743	BC037377					
Glutamate receptor, ionotropic, kainate 2	142077	AJ252246			+			Guanine nucleotide-binding protein $\gamma$ 7	51326	AB010414			+		
ATP-binding cassette, subfamily A member 8	78	AB020629						p21-Activated kinase 7	2122	AB030900				+	+
Hemicentin	217203	AF156100			+			Spectrin repeat containing, nuclear envelope 2	9450	AB023228			+		+
Family with sequence similarity 13 member C1	43164	BC036453						Lethal giant larvae homolog 2	1991	AK025401					
EMI domain containing 2	6846	AJ416091				+		ATP synthase, H+ transporting	1856	AF088071			+		
Zinc and ring finger 3	20847	AB051436			+			Chromosome 2 open reading frame 13	28872	BC030711					+
Similar to CG7467-PA	6095	XR_000268						Similar to hypothetical protein DKFZp666O0120.1	39692	XM_496490			+		+
Glycogen synthase kinase 3 $\beta$	71512	BC000251			+			START domain containing 9	68175	AB037721			+		+
$\gamma$ -Aminobutyric acid receptor $\rho$ 2	15479	M86888			+			KIAA1944 protein	293645	AB061814				+	+
Hypothetical protein FLJ22222	10514	AK025875			+			Spermatogenesis-associated 13	10701	AK055770					
Ankyrin repeat and SOCS box-containing 17	4339	AF403035			+		+	Hypothetical protein FLJ22301	1798	AK025954				+	+
Naked cuticle homolog NKD	7659	AB062886						Chromosome 10 open reading frame 11	364330	AF267860				+	+
Similar to IFIT1; Interferon, $\alpha$ -inducible protein	3368	XM_497244			+			Calcium channel voltage-dependent $\gamma$	13500	AF096322			+		
RAB31, member RAS oncogene family <sup>a</sup>	47283	AF183421			+			Similar to ribosome biogenesis protein BMS1 homolog	14205	XM_210011					+
Phosphodiesterase 8B	434	AB085824			+		+	<b>Total transcription factor sites</b>	<b>9</b>	<b>24</b>	<b>13</b>	<b>19</b>	<b>12</b>	<b>12</b>	

The nearest gene associated with the ER $\alpha$  – binding element from the ChIP library was identified by the human genome. The presence of ERE, AP-1, Sp1, NF $\kappa$ B, and FOXA1-binding sites in clones were determined by bioinformatics using programs described in *Materials and Methods*. The accession numbers were obtained from the National Center for Biotechnology Information database.

<sup>a</sup> Previously reported estrogen-regulated gene.

The execution of the biological effects of estrogens and SERMs is mediated by two ERs: ER $\alpha$  and ER $\beta$ . Once the ligand binds to these receptors, it induces a conformational change (8) that allows the receptor to interact with a regulatory element in target genes. Whereas the estrogen response element (ERE) is considered to be the major regulatory element in genes regulated by ERs (9), alternative elements, such as activator protein 1 (AP-1) (10) and Sp1 (11), are required for estradiol (E<sub>2</sub>) and SERMs to regulate the full spectrum of genes. When an estrogen-bound ER associates with a regulatory element, it recruits distinct classes of proteins, including p160s coactivators, mediator complex proteins, and cAMP response element-binding protein (CREB)-binding protein/p300, in a sequential and cyclical manner to activate gene transcription (12–14). In contrast, SERMs act as antagonists by recruiting corepressor proteins, such as nuclear receptor corepressor, that block the expression of the target gene (15). The mechanism of the agonist action that leads to transcriptional activation by SERMs is poorly understood but is thought to be mediated via the recruitment of coactivators to the activation function (AF)-1 domain of ERs (16, 17).

Although the ERE and alternative elements are important mediators of ER regulation of genes, the pharmacology of E<sub>2</sub> and SERMs on target genes cannot be understood solely by the known regulatory elements (18–20). For example, it is not yet known how E<sub>2</sub> distinctly regulates genes with ER $\alpha$  and ER $\beta$  (18, 21, 22) and how some genes regulated by tamoxifen are different from those regulated by raloxifene (18, 23). These observations indicate that in addition to the known regulatory elements, other types of elements exist in ER target genes. Identifying new regulatory elements in ER target genes is a critical step in the elucidation of how estrogens and SERMs induce the therapeutic and adverse effects observed in clinical trials. Previously, the standard way to identify ER-regulatory elements was to clone the promoter region and map the element with a series of deletion and point mutants upstream of a reporter gene. Recently, ER binding sites were identified by using a combination of chromatin immunoprecipitation (ChIP) and tiling arrays that contained chromosomes 21 and 22 (24) or the whole genome (25). ChIP also has been combined with sequencing to identify ER elements in MCF-7 cells (26). Here, we used a chromatin immunoprecipitation-cloning and sequencing (ChIP-CS) strategy to isolate genome-wide ER response elements from target genes in U2OS bone cells. Our goal was to assess the functional properties of a large set of ER-binding elements in response to different ligands. We isolated and tested 173 ER-regulatory elements for regulation by E<sub>2</sub>, raloxifene, and tamoxifen with both ER $\alpha$  and ER $\beta$ .

## RESULTS

### ChIP-Cloning and Sequencing Identifies ER $\alpha$ -Binding Elements

U2OS cells that express a stably transfected FLAG-ER $\alpha$  were treated for 2 h with E<sub>2</sub> and then were cross-linked with formaldehyde. After shearing the chromatin, the ER $\alpha$ -bound DNA fragments were isolated using an antibody against the FLAG epitope. DNA fragments were then further purified with an antibody against ER $\alpha$ . Isolated DNA fragments were cloned into plasmids, and 192 were randomly selected and sequenced. Bioinformatics was used to match the sequences in the ChIP-CS library to genes by performing a BLAST search against the human genome. Of the clones sequenced, 173 contained inserts, which ranged in size from 200–500 bp. The chromosomal identifier and sequence of the 173 elements is shown in supplemental Table 1 published as supplemental data on The Endocrine Society's Journals Online website at <http://mend.endojournals.org>. The location and name of each element relative to the nearest gene is shown in Tables 1 and 2.

### Many Elements Do Not Contain an ERE or Other Known ER-Regulatory Elements

We found that 38% of the regulatory elements were located in introns (Table 1); 24% of the regulatory elements were found less than 10 kb upstream region of the transcription start site (TSS), whereas the remaining 38% of the elements were located beyond 10 kb of the TSS (Table 2). A histogram shows the distance of the elements from the TSS (Fig. 1). To explore whether our ChIP-CS library contains authentic regulatory elements, we searched ER-responsive gene databases as well as our microarray data (18) for known ER target genes. We found that 10% of the genes in our ChIP-CS library were reported to be activated by E<sub>2</sub> or SERMs (Tables 1 and 2).

### Many Elements Do Not Contain an ERE or other Known ER-Regulatory Elements

We searched multiple databases, including TRANSFAC and Dragon ERE finder, to identify potential regulatory elements in the ChIP-CS library. Only 11% of the inserts contained classical EREs (Tables 1 and 2). AP-1, Sp1, FOXA1, or nuclear factor- $\kappa$ B (NF $\kappa$ B) sites were present in 41%, 18%, 24%, and 33% of the inserts, respectively (Tables 1 and 2). Surprisingly, 23% of the inserts did not have an ERE or one of the other alternative elements. These data support our hypothesis that additional types of regulatory elements exist in ER target genes.

**Table 2.** ER $\alpha$  Binding Sites Located in the Upstream Region of Target Genes

Gene Description	Location	Accession No.	ERE	AP-1	SP1	NF $\kappa$ B	FOXA1	Gene Description	Location	Accession No.	ERE	AP-1	SP1	NF $\kappa$ B	FOXA1
tRNA alanine	80	Gene ID: 4553			+			Receptor-interacting factor 1	23245	AK001826					
Single-stranded DNA binding protein 2 <sup>a</sup>	103	AA013030			+			Chemokine orphan receptor 1 <sup>a</sup>	26349	AF030297					
U2 small nuclear ribonucleoprotein A	112	AC002056			+			Myeloid/lymphoid or mixed-lineage leukemia	26492	AK057058	+				+
NADH dehydrogenase 6	154 and 884	AY063322						NYD-SP12 protein	26758	AF345909					
tRNA serine 1	266	Gene ID: 4574			+			Family with sequence similarity 34, member A	27290	BC034621					+
Calbindin 2, 29 kDa <sup>a</sup>	345	BC015484			+			Phosphodiesterase 4D interacting protein	29581	AB007923					
Hypothetical protein FLJ35827	347	AK093146			+			Similar to Ig $\kappa$ chain V region	30659 and 49654	XM_372941	+				+
Similar to olfactory receptor, family 7, subfamily A, 17	952	XM_497067			+			Similar to ADP, ATP carrier protein	36373	XM_498140					+
THAP domain containing 8	965	BC072416						Hypothetical gene supported by BC040860	38885	XM_498698					+
Retinal outer segment membrane protein 1	1020	BC008100			+			Hypothetical protein LOC389072	40610	BC020812					
Olfactory receptor, family 7	1121	AC064843			+			LOC441580	40920	XM_499193					+
Killer cell lectin-like receptor subfamily C, 3 <sup>a</sup>	1484 and 3100	AF027164			+			Cytidine monophosphate	41193	AF271388					+
Neuronal PAS domain protein 2	1328	AK026791			+			Similar to ATP-dependent DNA helicase II	41928	XM_372262					+
Snf2-related CBP activator protein	1551	AB002307			+			SNAP25-interacting protein	44729	AB051471					+
Hypothetical LOC401038	1940	XM_379163						Similar to eukaryotic translation elongation factor 1	48771	XM_497272					+
ATPase, Ca <sup>2+</sup> transporting, ubiquitous	2147	AF458229						Similar to putative	50229	XM_210400					+
FLJ46688 protein	2759	AK128530						Tankyrase TRF1-interacting ankyrin	51841	AF082556					+
KIAA0240	3021	AL833540			+			FAT tumor suppressor homolog 1 <sup>a</sup>	52081	D88798					+
Solute carrier family 4	3590	AB018282			+			Hypothetical protein MGC26143	52535	BC014590					+
Hypothetical gene supported by BC031617	3808	BC031617			+			Olfactory receptor family 4 subfamily C	52688	AC126345					+
fem-1 homolog b	3952	AB007856						Similar to 33-kDa protein	55690	XM_498064					+
Oligodendrocyte lineage transcription factor 2	4109	AF221520			+			Likely ortholog of mouse limb-bud and heart gene	56452	AF110224					
Polycystic kidney and hepatic disease 1	4442	AF480064			+			Ubiquitin-cytochrome c reductase	57627	AC007786					+
Complement component 1	4508	BC008983						Glutamate receptor ionotropic, $\delta$ 1	61700	AB033046					
Similar to zinc finger protein 92	4551	XM_066859			+			Hypothetical gene supported by AK094765	63164	XM_498861					+
Similar to salivary proline-rich protein	4645	XM_497733			+			Solute carrier family 8 member 1	65007	AC007281					+
Similar to nudix type motif 4 isoform $\beta$	4749	BT020109			+			Similar to FLJ10378 protein isoform 2	67385	Gene ID: 442109					+

(Table continues)


Table 2. Continued

Gene Description	Location	Accession No.	ERE	AP-1	SP1	NF-κB	FOXA1	Gene Description	Location	Accession No.	ERE	AP-1	SP1	NF-κB	FOXA1
Similar to seven transmembrane helix receptor	5219	XM_499490			+	+		Inter-α inhibitor H5	70933	AB075833	+			+	+
Similar to DEAD box polypeptide 10	5508	GeneID:401533						Similar to SPCPB16A4.07c	81779	XM_498163		+		+	
cAMP responsive element binding protein 3-like 2	5741	AJ549092		+		+		Forkhead box L1	83326	AF315075				+	
Sorting nexin family member 27	6195	AB007957	+	+			+	Hypothetical protein FLJ10305	89737	AK001167		+			
HR19, imprinted maternally untranslated mRNA <sup>a</sup>	6488	AC004556			+			Ribosomal protein L18 pseudogene 1	90890	AL512359				+	
Ig superfamily receptor	6490	AF329490		+				Similar to Ig heavy-chain-2 light-chain	95986	XM_372543					+
Homerin	7029	BR000036		+			+	SH2 domain containing 4B	98724	NM_207372				+	
Similar to TFIIH basal transcription factor	7206	GeneID:342784	+				+	Hypothetical protein LOC283432	120703	BC037211		+			
Transducin-like enhancer of split 2	7496	BC017364			+			Eukaryotic translation elongation factor 1 ε 1	122468	AB011079		+			
Progesterone receptor <sup>a</sup>	8931	AF016381					+	Hypothetical LOC285307	123535	XM_211837				+	
Hypothetical protein FLJ90586	9024	AK075067		+				Family with sequence similarity 10, member A3	149575	NG_004762					
Ubiquitin-conjugating enzyme E2N	9084	AK098233						Peptidylglycine α-amidating monooxygenase <sup>a</sup>	150061	AB095007		+			
Methylcrotonyl-Coenzyme A carboxylase 1	9317	BC004187			+	+		Hypothetical protein FLJ13197	160477	AK023259		+	+		
Similar to ribosome biogenesis protein BMS1 homolog	11530	XM_372108					+	Glycine receptor, α 1	187921	BC074980		+			+
Syntaxin-binding protein 6	12475	AF161505		+		+		7S1 cytoplasmic, pseudogene 2	196320	NG_002426					
Discoidin, CUB and LCC domain containing 2 <sup>a</sup>	12949	AB073146			+	+		Similar to Calcyclin binding protein	204123	AK093425					
Adrenergic, β, receptor kinase 2	13589	AK055687		+		+		Similar to Rpl7a protein	205123	XM_498041		+			
Polymerase II polypeptide D	14534	BC002958						Cadherin 18 type 2	246876	BC031051				+	+
Platelet-activating factor receptor <sup>a</sup>	14597	AY275466			+			Similar to RIKEN cDNA 573042E18 gene	298531	AK094007				+	+
Similar to galectin-related interferin protein	15092	XM_499395		+	+			Neuron navigator 3 <sup>a</sup>	307930	AB023155					
U56B small nuclear	17308	AC005994						Roundabout, axon guidance receptor	312713	AB046788		+			+
Coiled-coil domain containing 5	18850	AK097403		+		+		CUB and Sushi multiple domains 3	357892	AB067481				+	
UDP-glycosyltransferase 2 family polypeptide	19256	AF179879		+	+			Ribosomal protein L10-like	542861	AB063608	+	+	+		
FLJ45721 protein	20310	AK127623		+				Similar to chromosome 9 ORF 140	579108	BC048267				+	+
ρ Guanine nucleotide exchange factor 3	21857	AF249744		+			+	Hypothetical LOC389202	606000	XM_371690					
COMM domain containing 3	22486	AY542159						<b>Total transcription factor sites</b>			<b>10</b>	<b>47</b>	<b>18</b>	<b>38</b>	<b>29</b>

The nearest gene associated with the ERα-binding element from the ChIP library was identified by the human genome. The presence of ERE, AP-1, SP1, NF-κB, and FOXA1 binding sites in clones were determined by bioinformatics using programs described in *Materials and Methods*. The accession numbers were obtained from the National Center for Biotechnology Information database.

<sup>a</sup> Previously reported estrogen-regulated gene.






**Fig. 1.** Distances of Fragments from the Nearest Gene in the ChIP-CS Library Are Widely Distributed

Distances of each fragment to the nearest TSS (Tables 1 and 2) were plotted on a histogram. The y-axis represents the number of the clones, whereas the x-axis represents the distance of the clone to the nearest TSS.

### E<sub>2</sub> Recruits ER $\alpha$ and p160 Coactivators to Elements Derived from the ChIP Library in U2OS-ER $\alpha$ Cells

We selected elements from six genes to determine whether ER $\alpha$  binds to those elements in the native genes in U2OS-ER $\alpha$  cells. In these cells, the native ER $\alpha$  is driven by a tetracycline-inducible CMV promoter that allows for titration of the ERs to approximate physiological levels (18). ChIP shows that E<sub>2</sub> recruited ER $\alpha$  to the cat eye syndrome chromosome region candidate 6 (*CECR6*), spermatogenesis associated 13 (*SPATA13*), naked cuticle homolog (*NKD*), lethal giant larvae homolog 2, (*LLGL2*), *H19*, imprinted maternally expressed untranslated mRNA (*H19*), and killer cell lectin-like receptor subfamily C (*NKG2*) genes (Fig. 2). E<sub>2</sub> activates genes by recruiting p160 coactivators (14, 27), steroid receptor coactivator (SRC)1, SRC2 (transcriptional intermediary factor 2, glucocorticoid receptor interacting protein 1, and nuclear receptor coactivator 2), and SRC3 (pCIP, receptor-associated coactivator 3, amplified in breast cancer 1, and activator of thyroid and retinoic acid receptor) to the AF-2 surface of ER (28–30). Using ChIP, we examined whether E<sub>2</sub> recruits p160 coactivators to the six genes. E<sub>2</sub> produced a time-dependent recruitment of p160 coactivators to the six genes with maximal recruitment occurring at 1–2 h (Fig. 3). However, distinct coactivators were recruited to the genes. All three coactivators were recruited to the *CECR6* (Fig. 3A) and *H19* (Fig. 3E) genes, whereas SRC-2 and SRC-3 were recruited to *NKD* (Fig. 3C) and *NKG2* (Fig. 3F) genes. SRC-1 and SRC-2 were recruited to *LLGL2* (Fig. 3D), whereas only SRC-3 was recruited to the *SPATA13* (Fig. 3B) gene.



**Fig. 2.** ER $\alpha$  Interacts with Elements from the ChIP-CS Library


Tetracycline-inducible U2OS-ER $\alpha$  cells were treated with 10 nM E<sub>2</sub> for 3 h, and ChIP was performed using antibodies to ER $\alpha$ . Immunoprecipitated chromatin fragments were PCR amplified and quantitated by real-time PCR using primers for the *CECR6*, *SPATA13*, *NKD*, *LLGL2*, *H19*, and *NKG2* elements. Cont, Control.

### E<sub>2</sub> Activates and Recruits ER $\beta$ and p160 Coactivators to the *CECR6* and *NKD* Genes in U2OS-ER $\beta$ Cells

The regulation of *CECR6* and *NKD* genes by E<sub>2</sub> was also examined in the U2OS-ER $\beta$  cells. U2OS-ER $\beta$  cells were treated for increasing time with E<sub>2</sub>, and the levels of *CECR6* and *NKD* mRNA were measured by real-time PCR. E<sub>2</sub> produced a maximal activation of the *CECR6* gene in 6 h and at 3 h with the *NKD* gene (Fig. 4, A and B). The activation of the genes was associated with the recruitment of ER $\beta$  to the genes (Fig. 4, C and D). In contrast to the ER $\alpha$  cells, ChIP found that only SRC-2 was recruited by E<sub>2</sub> to the *CECR6* (Fig. 4E) gene, whereas SRC-1 and SRC-2 were recruited to the *NKD* (Fig. 4E) gene in the U2OS-ER $\beta$  cells. Maximal recruitment of the coactivators was observed after 2 h (Fig. 4, E and F). These findings demonstrate that both ER $\alpha$  and ER $\beta$  bind to the *CECR6* and *NKD* elements, but they recruit different p160 coactivators with E<sub>2</sub>.

### Tamoxifen Is More Effective at Regulating the Elements Than Raloxifene with ER $\alpha$ , Whereas Raloxifene Is Superior with ER $\beta$

The ChIP library represents a powerful set of regulatory elements to study the differential regulation by E<sub>2</sub>, tamoxifen, and raloxifene. The 173 elements were




**Fig. 3.** E<sub>2</sub> Recruits p160 Coactivators to Genes from the ChIP-CS Library

Tetracycline-inducible U2OS-ER $\alpha$  cells were treated with 10 nM E<sub>2</sub> for increasing times, and ChIP was performed using antibodies to the p160 coactivators, SRC-1, SRC-2, or SRC-3. Immunoprecipitated chromatin fragments were PCR amplified and quantitated by real-time PCR using primers for the *CECR6*, *SPATA13*, *NKD*, *LLGL2*, *H19*, and *NKG2* elements (panels A–F, respectively).

cloned upstream of the minimal thymidine kinase (tk) promoter and then transfected into wild-type U2OS cells with an ER $\alpha$  or ER $\beta$  expression vector. Cells were then treated with E<sub>2</sub>, tamoxifen, or raloxifene, and luciferase activity was measured. We found that 80% of the elements were regulated by at least one of the ligands with ER $\alpha$  or ER $\beta$  (Table 3). Many elements that were located outside the promoter region were regulated by the ligands (Table 3). Several regulated elements were located more than 500 kb from the transcription initiation site of the nearest gene. We also found that different elements derived from the same gene were differentially regulated by E<sub>2</sub>, tamoxifen, and raloxifene (Table 3, *boldface entries*). Some ele-

ments were differentially regulated by E<sub>2</sub>, tamoxifen, or raloxifene. Surprisingly, however, we found that even though the library was derived from cells expressing ER $\alpha$  and treated with E<sub>2</sub>, more elements were regulated by SERMs than E<sub>2</sub>. Moreover, E<sub>2</sub>, tamoxifen, and raloxifene activated more elements in the presence of ER $\beta$  compared with ER $\alpha$  (Table 3). We also found that more elements were activated by tamoxifen, compared with raloxifene, in the presence of ER $\alpha$ , whereas raloxifene was more effective than tamoxifen at activating the elements in the presence of ER $\beta$  (Table 4).

To compare the effects of the ligands on mRNA expression with the transfection results, we examined whether 35 genes randomly selected were regulated



**Fig. 4.** ER $\beta$  Activates the *CECR6* and *NKD* Genes and Recruits p160 Coactivators

Tetracycline-inducible U2OS-ER $\beta$  cells were treated with 10 nM E<sub>2</sub> for increasing times. *CECR6* (A) or *NKD* (B) mRNA was measured by qPCR. Each data point is the average of triplicate determinations  $\pm$  SEM. The asterisk represents a significant difference from control ( $P < 0.05$ ). ChIP assays were performed using antibodies to ER $\beta$  (C and D) and the p160 coactivators, SRC-1, SRC-2, or SRC-3 (E and F). Immunoprecipitated chromatin fragments were PCR amplified and quantitated by real-time PCR using primers for the *CECR6* (C and E) and *NKD* (D and F) elements. Cont, Control.

by E<sub>2</sub> and SERMs in the previously characterized, tetracycline-inducible U2OS-ER $\alpha$  cells (18). Cells were treated for various times with E<sub>2</sub>, tamoxifen, or raloxifene, and mRNA levels were determined by quantitative real-time PCR (qPCR). Similar to the transfection assays, several genes were regulated only by tamoxifen or raloxifene, even though the library was derived from cells treated with E<sub>2</sub>. Of the 35 genes examined, several showed good correlation with transfection assays. A similar pattern of regulation with transfection assays and qPCR were found with the *NKG2E*, *CECR6*, and *NKD* genes (Table 5). The EMI domain containing 2 and calbindin 2,29 kDa genes were acti-

vated with E<sub>2</sub> by qPCR, but E<sub>2</sub> did not activate the elements in transfection studies. In contrast, elements from the oligodendrocyte lineage transcription factor 2, fem-1 homolog b, protein tyrosine phosphatase, receptor type, M, and astrotactin genes were activated by SERMs in transfection assays, but were not activated by qPCR.

## DISCUSSION

Microarray data from our laboratory (18) showed that E<sub>2</sub> and SERMs exhibit a complex pattern of gene



Table 3. Effects of E<sub>2</sub> and SERMs on the Elements in the ChIP Library

Gene Name	ER $\alpha$			ER $\beta$			ER $\alpha$			ER $\beta$		
	E <sub>2</sub>	T	R	E <sub>2</sub>	T	R	E <sub>2</sub>	T	R	E <sub>2</sub>	T	R
	tRNA alanine	0.9	1.5	1.3	0.5	2.2	5.3	0.7	1.1	1.1	0.8	3.3
Single-stranded DNA-binding protein 2	0.9	1.3	1.2	0.5	2.4	3.1	1.0	2.0	1.2	0.7	1.4	1.5
u2 Small nuclear ribonucleoprotein A	0.8	1.1	3.8	1.0	2.9	7.3	0.9	1.9	1.6	0.9	1.8	2.5
<b>NADH dehydrogenase 6</b>	<b>0.9</b>	<b>2.0</b>	<b>1.5</b>	<b>0.6</b>	<b>3.4</b>	<b>7.2</b>	0.9	1.2	1.5	2.1	4.0	12.6
<b>NADH dehydrogenase 6</b>	<b>0.6</b>	<b>1.4</b>	<b>1.4</b>	<b>1.1</b>	<b>1.5</b>	<b>1.8</b>	<b>0.8</b>	<b>2.0</b>	<b>1.7</b>	<b>1.3</b>	<b>2.1</b>	<b>2.7</b>
tRNA serine 1	1.1	1.3	1.1	0.8	1.8	8.0	<b>0.9</b>	<b>0.8</b>	<b>1.3</b>	<b>0.7</b>	<b>2.6</b>	<b>5.6</b>
Calbindin 2.29 kDa	1.3	2.2	3.9	0.5	1.5	1.5	0.9	2.0	1.5	1.5	1.4	1.3
Hypothetical protein FLJ35827	1.0	1.5	1.2	0.6	2.6	4.1	0.5	1.2	1.6	1.2	4.5	7.0
THAP domain containing 8	1.0	1.3	1.6	0.8	1.1	1.7	0.7	0.7	0.7	0.8	0.7	0.8
Retinal outer segment membrane protein 1	0.7	1.1	1.2	1.0	2.0	3.2	1.1	2.8	2.0	1.3	1.3	1.3
Olfactory receptor, family 7	3.6	2.8	3.9	0.9	2.5	5.5	0.7	1.4	1.6	1.2	1.3	0.9
<b>Killer cell lectin-like receptor subfamily C</b>	<b>3.2</b>	<b>4.5</b>	<b>3.0</b>	<b>10.0</b>	<b>0.1</b>	<b>0.1</b>	0.9	0.8	0.9	1.0	0.8	0.9
<b>Killer cell lectin-like receptor subfamily C</b>	<b>1.1</b>	<b>1.2</b>	<b>1.1</b>	<b>0.6</b>	<b>3.9</b>	<b>5.5</b>	0.9	2.1	1.6	1.8	3.0	3.0
Neuronal PAS domain protein 2	2.5	4.3	2.6	0.8	2.2	3.4	0.8	1.2	1.4	0.7	2.3	3.4
Smf2-related CBP activator protein	0.8	1.6	1.4	0.1	1.2	1.9	1.0	0.9	0.8	1.3	3.4	4.9
Hypothetical LOC401038	0.5	1.5	1.3	0.3	6.4	9.0	0.9	1.3	1.3	2.3	6.9	4.8
ATPase, Ca <sup>2+</sup> -transporting, ubiquitous	1.4	2.2	2.8	0.4	3.4	5.5	0.9	1.9	2.2	0.4	2.9	2.8
FLJ46688 protein	0.6	1.3	1.5	0.7	2.6	3.3	0.6	1.3	1.5	0.7	2.4	5.2
KIAA0240	0.5	2.7	2.3	1.0	1.0	1.2	0.5	2.6	1.6	2.7	11.8	47.0
Solute carrier family 4	0.8	1.5	0.7	0.7	3.9	6.0	0.9	1.6	1.1	0.5	2.8	3.1
Hypothetical gene supported by BC031617	0.8	2.0	1.4	0.4	3.3	4.4	1.3	2.3	1.7	1.1	1.4	3.3
fem-1 homolog b	1.2	2.2	2.1	1.4	1.2	1.7	0.7	1.1	1.2	0.6	1.3	5.9
Oligodendrocyte lineage transcription factor 2	2.3	3.7	2.9	0.7	2.7	4.7	1.5	2.1	3.2	2.2	6.0	4.5
Polycystic kidney and hepatic disease 1	0.7	1.5	1.5	1.2	1.0	1.0	0.4	0.4	0.5	0.3	3.3	4.4
Complement component 1	1.1	1.7	1.3	0.8	0.7	0.8	0.8	2.0	2.7	0.3	4.7	8.0
Similar to zinc finger protein 92	0.6	1.2	1.3	1.2	2.5	4.0	1.0	1.7	1.3	1.1	1.1	1.2
Similar to salivary proline-rich protein	1.1	2.9	3.1	0.3	1.7	2.7	0.8	0.8	1.0	1.2	1.2	1.1
Similar to nudix type motif 4 isoform $\beta$	1.1	2.0	1.6	0.8	2.9	5.9	0.9	1.6	2.0	0.9	8.4	9.7
Similar to seven- transmembrane helix receptor	1.1	2.0	1.7	0.6	3.7	5.7	1.0	2.0	1.4	1.2	2.1	2.6
Similar to DEAD box polypeptide 10	1.5	0.9	1.1	0.7	2.4	6.3	0.8	1.7	1.9	1.0	1.7	4.0
cAMP-responsive element binding protein 3-like 2	0.8	1.3	1.5	0.7	2.9	6.2	0.8	0.7	0.8	0.7	2.9	4.4
Sorting nexin family member 27	1.2	3.1	3.6	0.9	2.0	5.6	1.3	1.0	1.1	1.5	1.5	1.1

(Table continues)

Table 3. Continued

Gene Name	ER $\alpha$			ER $\beta$			ER $\alpha$			ER $\beta$		
	E <sub>2</sub>	T	R	E <sub>2</sub>	T	R	E <sub>2</sub>	T	R	E <sub>2</sub>	T	R
H19, imprinted maternally expressed untranslated mRNA	0.9	2.5	2.1	0.8	1.2	1.2	0.8	1.5	1.5	0.8	3.4	7.3
Ig superfamily receptor	0.9	1.7	1.5	0.8	1.0	1.2	70.2	18.9	8.1	15.8	1.4	2.4
Homerin	1.0	1.5	1.5	1.7	2.0	8.4	0.7	1.7	1.7	3.4	1.4	2.0
Similar to TFIIH basal transcription factor	7.1	2.2	2.0	2.9	1.5	2.5	0.5	0.9	0.8	1.1	1.3	0.6
Transducing like enhancer of split 2	0.8	2.1	2.0	0.9	3.2	12.1	1.2	2.3	3.1	0.6	3.0	4.5
Progesterone receptor	1.1	1.0	1.3	0.8	2.0	6.5	1.1	0.9	0.7	0.8	0.9	0.8
Hypothetical protein FLJ90586	0.9	1.4	1.4	1.2	4.1	9.4	0.9	1.3	1.0	1.0	2.1	3.3
Ubiquitin-conjugated enzyme E2N	0.9	1.4	1.3	0.8	1.6	2.1	0.8	1.8	1.6	0.5	3.0	6.3
Mitochondrial coenzyme A carboxylase 1	0.8	1.7	1.8	0.9	1.0	1.5	1.6	2.2	1.3	1.0	1.2	1.3
<b>Similar to ribosome biogenesis protein BMS1 homolog</b>	<b>1.0</b>	<b>1.6</b>	<b>1.5</b>	<b>0.5</b>	<b>1.4</b>	<b>1.4</b>	1.0	2.0	1.5	0.8	2.8	5.1
Syntaxin-binding protein 6	1.0	1.3	1.0	0.7	2.1	3.3	0.8	0.6	0.8	0.9	1.1	1.4
Discoidin, CUB and LCCL domain containing 2	0.9	3.8	2.6	1.1	1.4	1.1	1.9	2.1	3.5	1.0	1.6	1.6
Adrenergic $\beta$ receptor kinase 2	0.9	1.3	1.3	0.5	0.9	1.0	0.7	1.1	0.9	1.1	3.7	4.5
Polymerase II polypeptide D	0.8	1.9	1.7	1.2	2.5	3.2	1.0	2.5	2.1	0.4	2.6	3.6
Platelet-activating factor receptor	1.3	1.3	1.3	0.7	1.0	0.9	0.8	1.4	1.2	0.8	1.0	0.6
Similar to galectin-related inter-fiber protein	0.7	2.0	1.7	0.4	3.4	6.9	1.3	2.3	2.1	0.8	1.3	1.8
US6B small nuclear	0.9	1.8	1.6	0.8	1.3	1.3	0.8	1.6	1.3	0.6	4.0	5.5
Coiled-coil domain containing 5	1.1	1.3	1.4	0.7	1.1	0.8	24.6	2.5	1.5	0.3	4.1	5.1
UDP glycosyltransferase 2 family, polypeptide	0.9	1.3	1.4	1.2	2.9	9.2	3.5	2.5	1.5	2.4	2.3	2.1
FLJ45721 protein	0.3	0.7	0.7	0.6	3.4	4.0	1.1	2.0	1.6	0.7	5.2	11.3
$\rho$ -Guanine nucleotide exchange factor 3	1.1	1.6	1.7	1.6	1.9	1.2	1.0	2.2	1.6	1.1	2.2	2.9
COMM domain containing 3	1.0	1.5	1.3	1.2	1.1	1.4	0.8	1.4	1.8	2.5	4.1	4.1
Receptor-interacting factor 1	1.4	2.4	1.8	1.2	4.0	8.9	1.0	2.7	2.7	0.8	1.2	1.5
Chemokine orphan receptor 1	1.1	7.4	2.9	0.9	4.3	7.2	1.5	2.4	2.0	1.0	1.8	2.9
Myeloid/lymphoid or mixed-lineage leukemia	0.6	0.8	1.0	0.7	1.3	1.4	0.7	1.0	1.0	0.6	3.1	4.3
NVD-SP-12 protein	0.6	1.6	1.5	1.3	0.9	1.0	0.5	1.3	1.7	0.4	5.6	11.6
Family with sequence similarity 34, member A	0.7	1.0	1.4	0.3	1.5	1.8	0.6	1.2	1.5	0.5	3.9	5.7
Phosphodiesterase 4D-interacting protein	0.9	0.9	1.0	0.6	4.5	6.2	0.6	1.2	1.3	0.4	1.8	2.5
<b>Similar to Ig <math>\kappa</math> chain V region</b>	<b>0.6</b>	<b>1.0</b>	<b>0.9</b>	<b>0.5</b>	<b>3.1</b>	<b>4.5</b>	0.7	1.1	1.2	1.0	1.8	1.5
<b>Similar to Ig <math>\kappa</math> chain V region</b>	<b>1.0</b>	<b>0.9</b>	<b>1.3</b>	<b>1.1</b>	<b>2.5</b>	<b>3.3</b>	1.0	2.1	1.4	0.5	3.6	5.6
Similar to ADP, ATP carrier protein	4.6	9.4	4.5	0.6	4.3	6.1	0.7	1.4	1.4	1.2	1.1	1.1
Hypothetical gene supported by BC040860	0.4	1.1	1.1	0.8	4.8	6.5	1.0	1.4	2.1	0.6	2.9	6.4
Hypothetical protein LOC389072	0.5	1.4	1.1	1.0	1.7	2.9	0.9	2.6	2.0	0.4	2.9	6.6

(Table continues)

Table 3. Continued

Gene Name	ER $\alpha$			ER $\beta$			ER $\alpha$			ER $\beta$		
	E <sub>2</sub>	T	R	E <sub>2</sub>	T	R	E <sub>2</sub>	T	R	E <sub>2</sub>	T	R
LOC441580	1.0	2.6	2.0	0.4	2.4	3.9	0.8	1.2	1.2	0.8	2.0	3.4
Cytidine monophosphate	0.8	1.1	0.9	0.5	3.0	3.5	1.1	2.2	2.2	0.6	3.9	7.0
Similar to ATP-dependent DNA helicase II	0.9	0.9	0.7	1.2	3.2	7.0	0.9	1.6	1.6	0.4	2.5	2.9
SNAP25-interacting protein	0.6	1.7	1.6	0.6	3.0	4.8	0.8	0.9	0.6	0.6	3.8	4.7
Similar to eukaryotic translation elongation factor 1	1.6	3.9	2.4	1.0	1.8	3.9	0.7	1.6	1.4	1.0	1.7	2.0
Similar to putative	0.8	1.2	1.1	0.7	2.3	5.0	1.0	2.0	1.7	1.1	1.3	2.4
Tankyrase, TRF1-interacting ankyrin	0.5	1.6	1.3	1.2	2.4	5.5	0.6	1.7	1.9	1.0	1.1	1.9
FAT tumor suppressor homolog 1	0.8	1.4	1.2	0.6	1.1	1.8	0.6	1.4	1.3	0.9	0.6	0.6
Hypothetical protein MGC26143	0.5	0.8	1.1	0.6	3.5	5.1	0.9	1.6	1.3	0.6	5.4	6.0
Olfactory receptor, family 4, Subfamily C	0.8	1.4	1.5	1.2	2.1	2.9	0.7	0.8	0.9	0.8	1.2	1.6
Similar to 33 kDa protein	1.1	1.1	1.0	0.7	1.0	1.7	0.7	1.2	1.4	1.0	1.2	1.5
Likely ortholog of mouse limb-bud and heart gene	1.6	2.7	1.8	1.0	2.3	2.5	1.7	1.9	1.4	0.6	2.1	1.9
Ubiquinol-cytochrome c reductase	0.7	1.3	1.1	0.9	1.7	3.3	0.7	1.2	1.6	0.6	1.9	2.7
Glutamate receptor, ionotropic, $\delta$ 1	1.2	1.5	1.7	0.9	1.8	3.2	0.6	1.4	1.4	0.3	2.4	3.0
Hypothetical gene supported by AK094765	0.6	1.1	1.4	0.6	2.1	2.4	1.4	1.9	1.3	0.7	1.9	3.4
Solute carrier family 8 member1	1.0	1.9	2.0	1.0	1.9	4.1	0.9	1.3	1.4	1.7	0.4	1.2
Similar to FLJ10378 protein isoform 2	1.2	1.3	1.3	0.6	2.3	2.7	0.6	1.3	1.3	0.7	1.6	3.3
Inter- $\alpha$ inhibitor H5	1.0	1.4	1.3	0.9	1.0	1.4	0.9	1.4	1.4	1.0	1.6	2.5
Similar to SPCPB16A4.07c	1.1	2.2	1.5	1.0	2.3	2.7	0.6	0.9	1.1	0.5	4.1	6.4
Forkhead box L1	0.9	1.6	1.5	0.7	1.7	1.3	1.2	2.1	1.7	1.0	2.5	7.7
Hypothetical protein FLJ10305	0.9	1.7	1.4	0.4	3.5	5.8	<b>0.7</b>	<b>1.4</b>	<b>1.5</b>	<b>0.6</b>	<b>0.8</b>	<b>1.8</b>
Ribosomal protein L18_pseudogene 1	0.9	1.4	1.2	0.9	1.1	1.3						

Wild-type U2OS cells were transfected with the different elements from the ChIP library, located upstream of the minimal tk promoter, and an ER $\alpha$  or ER $\beta$  expression vector. Cells were then treated with 10 nM E<sub>2</sub>, 1  $\mu$ M tamoxifen or 1  $\mu$ M raloxifene for 18 h and luciferase assays were performed. *Boldface entries* indicate different elements located adjacent to one gene. Each number represents the mean of three measurements. The SEM was less than 10%. T, Tamoxifen; R, raloxifene.

**Table 4.** Summary of the Genes Activated by E<sub>2</sub>, Tamoxifen, and Raloxifene

	No. of Genes Regulated by 2-Fold or More
<b>ER<math>\alpha</math></b>	
Estradiol	19
Tamoxifen	51
Raloxifene	34
Tamoxifen > raloxifene	13
Raloxifene > tamoxifen	6
<b>ER<math>\beta</math></b>	
Estradiol	38
Tamoxifen	94
Raloxifene	116
Tamoxifen > raloxifene	3
Raloxifene > tamoxifen	75

The numbers listed are for genes activated with the drug by at least 2-fold. For the genes listed for tamoxifen vs. raloxifene the magnitude of activation by one of the drugs ER $\alpha$  and ER $\beta$  was at least 1.5-fold greater.

regulation that cannot be explained by the pharmacology of known ER-responsive elements such as ERE, AP-1, and Sp1. These data raise the possibility that many ER target genes contain unknown regulatory elements. Whereas microarrays easily identify ER target genes (19, 21, 31) they do not provide any information on the location or nature of the regulatory elements in the target gene. Thus, new genome-wide approaches are essential to rapidly isolate regulatory elements in target genes to understand how E<sub>2</sub> and SERMs exert tissue-specific clinical effects and produce the complex gene expression profiles observed with microarrays.

ChIP-chip is a powerful strategy that has been used to identify elements in target genes for ER $\alpha$  (25, 35–37). This approach is valuable to identify and annotate different classes of ER elements and to identify transcription factors that interact with ER-binding sites (25). Here we used a ChIP-CS strategy to rapidly isolate and characterize ER-regulatory elements. We isolated 173 ER-binding elements that were tested for functional activity in response to E<sub>2</sub> and SERMs with ER $\alpha$  and ER $\beta$ .

We found that most elements were derived from introns and regions beyond 10 kb of the TSS. Only 24% of the elements were found within 10 kb of the TSS. ChIP-chip studies also showed that many ER-regulatory elements are located at a distance far from the TSS (24, 25). It also has been shown that 63% of the glucocorticoid response elements are found beyond 10 kb of the TSS (39). These results demonstrate that the proximal promoter region only contains a small subset of response elements for steroid receptors.

Only 11% of the genes derived from the ChIP-CS library had an ERE despite the use of a fairly low stringency for detection. Although the ERE is considered to be the major response element in target genes,

these results suggest that most ER target genes are regulated by response elements other than the classical ERE. Of the elements in the ChIP-CS library, 41% contained an AP-1 site, whereas 18% of the genes contained Sp1 elements. The most surprising finding was that 23% of the clones from the ChIP library did not contain an ERE or any of the known alternative elements. However, our transfection studies showed that 70% of the elements without a classical ERE, AP-1, Sp1, FOXA1, or NF $\kappa$ B element were regulated by E<sub>2</sub> or SERMs, demonstrating that many regulatory sequences from the ChIP library contain unknown elements. This notion was supported by the data showing that E<sub>2</sub> activated and recruited p160s coactivators to the *NKD* gene, which did not have any known regulatory element.

A major advantage of having numerous elements from the ChIP library is that they can be examined for activity with different ligands and ERs. Most of the 173 elements were regulated by E<sub>2</sub>, tamoxifen, or raloxifene with ER $\alpha$  or ER $\beta$  using transfection assays, demonstrating that the library contained genuine regulatory elements. By testing a large number of elements, we were able to discover several surprising and interesting observations. We found that more elements were regulated by SERMs, even though ChIP was done with E<sub>2</sub>-treated cells. One explanation for this finding is that E<sub>2</sub> regulation might require other factors that are lost during shearing of the chromatin. Genome-wide tiling arrays showed that many ER-binding sites are associated with transcription factor elements, such as FOX1A, AP-1, Oct, and CCAAT enhancer binding protein, which are important for regulation by E<sub>2</sub> (25). Our findings suggest that the E<sub>2</sub>-ER complex binds to the elements and is recognized by the ChIP antibody. However, some elements are probably functionally inactive because the ER is unable to interact with factors that are absent from the ChIP element and required for transcriptional regulation by E<sub>2</sub>. Alternatively, it is conceivable that the antibody, which we used for ChIP, selectively recognizes an ER conformation that is inactive or inhibitory when bound to E<sub>2</sub>. Other antibodies, such as the one used in the tiling arrays (25), might recognize an ER conformation that is capable of detecting elements activated by E<sub>2</sub>. Finally, it is likely that some of the ER-binding sites might be silent in U2OS cells and do not function as regulatory elements in response to E<sub>2</sub>. Some of these inactive elements might be regulated by E<sub>2</sub> in other cell types.

Another important finding from the functional studies of the ChIP library was that the magnitude of activation of most elements by tamoxifen was greater with ER $\alpha$ , whereas raloxifene was more effective at activating the elements in the presence of ER $\beta$ . The reason for the differences in activation with the two receptor subtypes is unclear. Tamoxifen binds equally to ER $\alpha$  and ER $\beta$  (40), whereas raloxifene binds with about 2-fold greater affinity to ER $\beta$  than ER $\alpha$  (41). These results demonstrate that differences in binding do not account for the difference in the activity of

**Table 5.** Comparison of the Regulation of Selected Elements and Genes by E<sub>2</sub> and SERMs

	Estradiol			Tamoxifen			Raloxifene					
	Luc.	PCR	Luc	Luc	PCR	Luc	Luc	PCR	Luc			
Killer cell lectin-like receptor subfamily C	32.0	20.6 ± 9.7	43.5 ± 6.7	86.1 ± 11.2	4.5	5.6 ± 1.2	8.2 ± 7.8	17.3 ± 14.6	3.0	1.8 ± 0.7	4.1 ± 1.6	7.0 ± 3.0
Cat eye syndrome chromosome region candidate 6	70.2	29.9 ± 2.2	39.4 ± 2.4	13.0 ± 1.0	18.9	2.5 ± 0.4	2.6 ± 0.8	4.0 ± 0.4	8.1	0.9 ± 0.1	1.1 ± 0.0	1.3 ± 1.0
H19, imprinted maternally expressed untranslated mRNA	0.9	10.4 ± 4.6	11.2 ± 0.9	12.7 ± 2.2	2.5	1.7 ± 0.4	2.4 ± 0.4	1.9 ± 0.2	2.1	0.9 ± 0.2	1.1 ± 0.4	0.9 ± 0.2
EMI domain containing 2	1.9	4.2 ± 1.2	3.6 ± 1.6	3.4 ± 2.6	2.1	1.4 ± 0.3	1.8 ± 0.5	1.4 ± 0.1	3.5	1.6 ± 0.5	2.1 ± 1.4	1.8 ± 1.2
Retinal outer segment membrane protein 1	0.7	3.2 ± 2.2	2.4 ± 0.1	8.8 ± 7.1	1.1	1.9 ± 0.2	1.8 ± 0.4	1.7 ± 0.3	1.2	0.7 ± 0.4	4.4 ± 1.0	2.5 ± 1.8
Naked cuticle homolog	3.5	2.5 ± 0.2	2.3 ± 0.3	2.1 ± 0.2	2.5	2.6 ± 0.9	2.2 ± 0.1	1.9 ± 0.3	1.5	1.1 ± 0.1	1.3 ± 0.3	1.1 ± 0.1
Solute carrier family 4	0.8	2.2 ± 0.0	3.2 ± 0.9	3.5 ± 0.8	1.5	0.7 ± 0.2	2.4 ± 0.1	2.7 ± 0.6	0.7	0.9 ± 0.2	1.0 ± 0.1	1.0 ± 0.1
Spermatogenesis associated 13	0.6	2.8 ± 0.5	2.5 ± 0.5	1.7 ± 0.4	1.3	2.5 ± 0.9	3.2 ± 0.7	3.5 ± 1.1	1.3	1.8 ± 0.7	2.2 ± 0.5	2.4 ± 0.6
Calcium channel L-type α 1B subunit	0.8	1.4 ± 0.0	1.9 ± 0.3	3.7 ± 0.5	0.7	1.1 ± 0.0	1.3 ± 0.2	1.2 ± 0.1	0.8	0.8 ± 0.2	0.9 ± 0.1	1.1 ± 0.2
Cytoplasmic polyadenylation element bp 4	0.4	1.9 ± 0.3	2.1 ± 0.0	2.1 ± 0.4	0.4	1.3 ± 0.2	1.1 ± 0.1	1.7 ± 1.0	0.5	1.0 ± 0.4	1.0 ± 0.1	1.0 ± 0.1
Glutamate receptor ionotropic kainate 4	0.7	1.0 ± 0.4	1.0 ± 0.1	2.8 ± 0.0	1.4	0.3 ± 0.0	0.1 ± 0.0	1.2 ± 0.6	1.4	0.4 ± 0.0	0.4 ± 0.1	0.7 ± 0.4
Galbindin 2,29 kDa	1.3	1.8 ± 0.2	2.4 ± 0.1	2.7 ± 0.0	2.2	1.0 ± 0.0	1.6 ± 0.3	1.3 ± 0.2	3.9	1.0 ± 0.3	2.4 ± 0.1	2.3 ± 0.0
UDP glycosyltransferase 2 family, polypeptide	0.9	1.0 ± 0.2	1.4 ± 0.4	2.9 ± 0.3	1.3	1.0 ± 0.0	1.1 ± 0.0	1.3 ± 0.1	1.4	1.3 ± 0.5	0.9 ± 0.5	1.7 ± 0.7
Chromosome 10 open reading frame 11	0.6	1.0 ± 0.2	1.0 ± 0.2	0.9 ± 0.2	0.9	0.8 ± 0.1	0.8 ± 0.3	0.4 ± 0.1	1.1	0.8 ± 0.2	0.8 ± 0.2	0.6 ± 0.1
Solute carrier family 19 member 1	0.7	1.2 ± 0.3	0.8 ± 0.2	0.8 ± 0.0	1.7	0.9 ± 0.1	0.8 ± 0.2	0.5 ± 0.0	1.7	1.1 ± 0.1	1.2 ± 0.3	1.1 ± 0.3
Eukaryotic translation elongation factor 1 ε 1	0.9	0.8 ± 0.1	0.6 ± 0.0	0.9 ± 0.3	1.2	0.7 ± 0.1	0.7 ± 0.1	1.7 ± 0.2	1.5	0.6 ± 0.3	0.7 ± 0.4	1.0 ± 0.1
Protocadherin 11 X-linked	1.0	1.1 ± 0.1	0.9 ± 0.4	0.5 ± 0.0	1.7	1.1 ± 0.1	1.7 ± 0.2	1.7 ± 0.3	1.3	0.8 ± 0.2	0.9 ± 0.3	0.7 ± 0.1
START domain containing 9	1.4	0.5 ± 0.0	0.5 ± 0.2	0.5 ± 0.1	1.9	0.9 ± 0.1	0.9 ± 0.0	0.9 ± 0.1	1.3	0.6 ± 0.2	0.9 ± 0.0	0.9 ± 0.1
Single-stranded DNA binding protein 2	0.9	0.7 ± 0.1	0.4 ± 0.1	0.5 ± 0.0	1.3	0.6 ± 0.1	0.7 ± 0.1	0.5 ± 0.1	1.2	0.7 ± 0.0	1.2 ± 0.4	0.9 ± 0.2
Putative nuclear protein ORF1-FL49	1.0	0.5 ± 0.0	0.5 ± 0.1	0.6 ± 0.0	2.1	0.9 ± 0.1	1.0 ± 0.2	0.8 ± 0.1	1.4	0.7 ± 0.0	1.2 ± 0.6	1.1 ± 0.3
I (3) mbt like 2	0.9	0.9 ± 0.2	0.5 ± 0.1	0.5 ± 0.0	1.3	0.8 ± 0.1	0.8 ± 0.1	0.8 ± 0.1	1.0	0.9 ± 0.1	1.3 ± 0.3	1.1 ± 0.3
Plasminogen like	0.7	1.2 ± 0.2	0.6 ± 0.2	0.4 ± 0.1	1.6	1.2 ± 0.1	1.0 ± 0.2	0.9 ± 0.2	1.4	0.8 ± 0.2	0.9 ± 0.1	1.2 ± 0.4
RNA binding motif single strand interacting protein	1.3	0.4 ± 0.0	0.3 ± 0.1	0.4 ± 0.1	1.0	0.6 ± 0.2	0.4 ± 0.2	0.4 ± 0.1	1.1	0.7 ± 0.1	0.7 ± 0.1	0.8 ± 0.2
Glutamate receptor ionotropic kainate 2	0.8	0.7 ± 0.5	1.1 ± 0.1	0.2 ± 0.0	1.8	1.0 ± 0.2	1.9 ± 0.5	1.6 ± 0.6	1.6	0.9 ± 0.1	0.8 ± 0.1	1.0 ± 0.3
CUB and sushi multiple domains1	0.8	1.0 ± 0.1	1.0 ± 0.0	1.3 ± 0.0	1.7	0.8 ± 0.2	1.0 ± 0.3	1.0 ± 0.5	1.9	0.8 ± 0.1	0.9 ± 0.4	1.1 ± 0.1
Fibroblast growth factor 12	0.6	0.8 ± 0.0	0.9 ± 0.2	1.1 ± 0.0	1.2	0.9 ± 0.2	1.0 ± 0.2	1.1 ± 0.1	1.3	0.9 ± 0.0	1.1 ± 0.4	0.9 ± 0.2
Adenosine deaminase RNA specific B1	0.8	1.6 ± 0.2	1.1 ± 0.4	1.3 ± 0.5	0.9	0.8 ± 0.1	0.7 ± 0.1	0.7 ± 0.1	0.6	0.7 ± 0.3	1.1 ± 0.1	0.9 ± 0.2
Protein tyrosine phosphatase, receptor type, M	1.5	1.1 ± 0.2	1.2 ± 0.3	1.3 ± 0.5	2.1	1.2 ± 0.1	1.8 ± 0.1	1.7 ± 0.2	3.2	0.8 ± 0.1	1.2 ± 0.5	1.0 ± 0.2
COMM domain containing 3	1.0	1.3 ± 0.3	1.1 ± 0.3	1.2 ± 0.4	1.5	1.0 ± 0.3	1.3 ± 0.4	1.6 ± 0.3	1.3	0.8 ± 0.2	0.8 ± 0.2	1.1 ± 0.2
Phosphodiesterase 8B	0.8	1.4 ± 0.2	1.3 ± 0.3	1.2 ± 0.2	1.4	0.8 ± 0.3	0.8 ± 0.3	1.1 ± 0.2	1.8	0.7 ± 0.1	1.4 ± 0.5	0.8 ± 0.2
Astrotactin	1.5	0.7 ± 0.0	0.8 ± 0.0	1.1 ± 0.1	2.4	1.0 ± 0.2	1.0 ± 0.3	0.9 ± 0.1	2.0	0.9 ± 0.1	1.1 ± 0.4	1.0 ± 0.2
Fem-1 homolog b	1.2	1.0 ± 0.2	1.1 ± 0.1	1.2 ± 0.1	2.2	0.8 ± 0.0	1.1 ± 0.0	0.7 ± 0.1	2.1	0.7 ± 0.1	1.2 ± 0.3	1.1 ± 0.1
Hypothetical protein FLJ30707	1.1	0.6 ± 0.2	0.6 ± 0.0	0.8 ± 0.2	0.9	0.9 ± 0.1	1.0 ± 0.1	0.8 ± 0.2	0.7	1.0 ± 0.2	1.0 ± 0.1	0.9 ± 0.1
cAMP responsive element binding protein 3-like 2	0.8	0.8 ± 0.1	1.1 ± 0.0	1.1 ± 0.0	1.3	0.8 ± 0.2	1.2 ± 0.3	1.0 ± 0.2	1.5	1.1 ± 0.0	1.2 ± 0.3	1.3 ± 0.1
Oligodendrocyte lineage transcription factor 2	2.3	0.7 ± 0.2	0.8 ± 0.2	0.9 ± 0.4	3.7	1.0 ± 0.1	1.0 ± 0.1	0.8 ± 0.0	2.9	1.0 ± 0.1	1.3 ± 0.2	1.2 ± 0.0
Time of treatment (h)	18	6	12	24	18	6	12	24	18	6	12	24

Luciferase activity of the elements was measured by transfection studies. The expression of the corresponding gene was measured by real-time PCR after 6, 12 and 24 h of treatments with the ligands in U2OS-ERα cells. Each data point is the average of triplicate determinations ± SEM.



tamoxifen and raloxifene with ERs. Structural studies found that tamoxifen and raloxifene produce different conformations of ER $\alpha$ , with raloxifene causing a greater increase in the mobility of helix 12 of the ligand-binding domain (30). The different conformations elicited by tamoxifen and raloxifene might lead to a differential binding of ERs to the regulatory elements or the recruitment of different coregulators by ER $\alpha$  and ER $\beta$  at the elements. We previously showed that tamoxifen and raloxifene activate the *NKG2E* gene by recruiting different coactivators (42). We also found that tamoxifen activated the *CECR6* and *NKD* genes from the ChIP library by recruiting coactivators (data not shown). In contrast, raloxifene did not activate these genes or recruit coactivators. These results indicate that the SERMs produce different conformations in ER, which leads to the differential recruitment of coactivators. The observation that the agonist activity of SERMs is mediated by coactivators is consistent with the findings that coactivators can interact with the AF-1 in the A/B domain (16, 17).

One of the more surprising findings was the lack of correlation between the gene expression data and transfection studies. Previous studies selected a few elements derived from ChIP to correlate gene expression with function in response to E<sub>2</sub> with transfection studies (25, 26). To avoid any potential bias in selecting elements to examine, we cloned all 173 elements from the library upstream of tk-luciferase. Only a few of the 35 genes that were tested for expression data by PCR showed an exact correlation with transfection assays. There are several possible explanations for these findings. First, the element from the ChIP library was assigned to the nearest gene. However, it is possible that the element actually regulates one of the other three adjacent genes, rather than the nearest gene. Second, because of compact folding of chromatin, the regulatory element isolated from the ChIP library could actually be in close proximity to distant target genes. It is well recognized that enhancers can operate at far distances (43). For example, the E2 enhancer region interacts with distant Sp1 transcription factors by forming stable DNA loops that can be visualized by electron microscopy (44). These findings suggest that the elements from the ChIP library might bypass adjacent genes and cause regulation of distant ER target genes. Third, it is likely that some regulatory elements function differently in the context of native genes. Genes also contain silencers, which are elements that bind repressor proteins that repress the activation of the gene. Thus, some elements from the ChIP library that are functional when isolated and inserted upstream of the tk promoter might be silenced by other factors that interact with the native gene. This might be an important mechanism for tissue-specific gene expression if the factors are differentially expressed in different cell types. The results from our qPCR and luciferase data suggest that it is highly probable that the element actually regulates the assigned gene only when there is good correlation be-

tween ER binding by ChIP, mRNA expression, and transfection data.

Our results suggest that many ER target genes are regulated by elements other than ERE, AP-1, Sp1, FOXA1, and NF $\kappa$ B. We performed extensive bioinformatic analysis of the elements to identify other motifs that might be involved in regulation by ER. However, we were unable to discover any new motifs present in the majority of elements. This might be due to the fact that the ChIP library contained too few genes to detect new motifs. However, our detailed analysis of one element from the ChIP library (42) suggests it will be extremely difficult to detect single motifs even with many more elements. We found that the *NKG2E* gene contains a complex composite element (45), which comprises four elements (AP-1, heat shock factor-2, CCAAT enhancer binding protein- $\beta$ , and a variant ERE) that cooperate to regulate the gene by E<sub>2</sub> and SERMs (42). The results with the *NKG2E*-regulatory element and our ChIP library, showing that different elements, even within the same gene, are differentially regulated by E<sub>2</sub>, tamoxifen, and raloxifene, suggest that many ER targets are regulated by a combination of cooperative elements rather than a single element, such as ERE, AP-1, and Sp1. The tiling arrays suggest that ER cooperates with a preferred set of transcription factors (25). However, our data suggest that many different combinations of factors interact with ER, because we were unable to detect any consistent combination of elements in the ChIP library. Furthermore, it is also likely that the factors with which ER interacts to regulate genes varies in different cell types. This notion is consistent with our observation that some of the ChIP library elements were regulated differently by E<sub>2</sub> and SERMs in various cell types (data not shown).

The data from our ChIP library and tiling arrays clearly indicate that most ER target genes are regulated by ER interacting with a combination of multiple different transcription factors, rather than binding exclusively to an ERE. Identifying combinatorial regulatory elements will likely require detail mapping of many elements with functional studies. The isolation of regulatory elements from native genes with techniques such as ChIP-CS is a major step toward understanding how ER $\alpha$  and ER $\beta$  regulate different genes in response to diverse ligands, and how E<sub>2</sub> and SERMs produce unique clinical effects. However, our findings also suggest that whereas ChIP-chip and ChIP-CS can identify ER-binding sites and regulatory elements, it can be difficult to identify the exact gene that is regulated by the element, even when the element is in close proximity or within a gene. A major challenge will be to develop strategies to accurately assign the proper gene that is regulated by the elements identified with tiling arrays or sequencing.



## MATERIALS AND METHODS

### Preparation of Stable Cell Lines

U2OS cells stably expressing Flag-tagged ER $\alpha$  were prepared by transfecting wild-type U2OS cells with pcDNA 6/V5-His vector containing Flag-ER $\alpha$ . Cells were selected and maintained using 10  $\mu$ g/ml blasticidin. Tetracycline-inducible U2OS-ER $\alpha$  and U2OS-ER $\beta$  cells were prepared, characterized, and maintained as previously described (18).

### Chromatin Immunoprecipitation Cloning and Sequencing (ChIP-CS)

U2OS-Flag-ER $\alpha$  cells were treated with 10 nM E<sub>2</sub> for 2 h and then cross-linked, washed, collected, and lysed as previously described (18, 46). Nuclei were then resuspended in FLAG protein immunoprecipitation buffer (50 mM Tris HCl, pH 7.4; 150 mM NaCl; 1 mM EDTA; 1% Triton X-100) and sonicated. The supernatant fraction was collected and incubated with anti-flag M2 agarose beads (Sigma-Aldrich, St. Louis, MO) for 2 h at 4 C. After the beads were washed (0.05 M Tris HCl, pH 7.4; 0.15 M NaCl), the proteins were eluted using 150 ng/ $\mu$ l 3X FLAG peptide (Sigma-Aldrich) in 0.05 M Tris HCl (pH 7.4)-0.15 M NaCl. Eluted proteins were then incubated with anti-ER $\alpha$  (DAKO Corp., Carpinteria, CA) coated magnetic beads (Dynabeads M-280) for 2 h. Beads were washed with PBS containing 1% BSA, and cross-linking of DNA/proteins was reversed with 1% sodium dodecyl sulfate-0.1 M NaHCO<sub>3</sub> at 65 C. DNA fragments were purified, (QIAquick PCR Purification Kit; QIAGEN, Chatsworth, CA), blunt ended, and cloned, and plasmids were isolated and sequenced (Lark Technologies, Houston, TX).

### Plasmids, Transfections, and Luciferase Assays

Inserts from the plasmids were cloned upstream of -32 to +45 tk-luciferase. Transfections of the various vectors into U2OS cells were carried out by electroporation (47). Cells were assayed for luciferase activity according to manufacturer's protocol (Promega Corp., Madison, WI).

### RNA Extraction and Quantitative Real-Time PCR

Total RNA was extracted and then treated with DNase using the Aurum Total RNA Mini Kit (Bio-Rad Laboratories, Hercules, CA). Reverse transcription reactions were performed using the iScript cDNA Synthesis Kit with 1  $\mu$ g of total RNA as previously described (48). qPCR was performed with a Bio-Rad iCycler Thermal Cycler System using iQ SYBR Green Supermix (Bio-Rad). Mean  $\pm$  SEM was calculated using Prism curve-fitting program (GraphPad Software, Inc., San Diego, CA). The primers used for qPCR are listed in supplemental Table 2.

### Chromatin Immunoprecipitation (ChIP)

After treatments, cells were cross-linked, washed, collected, and lysed as described above. Immunoprecipitations were performed overnight at 4 C with anti-ER $\alpha$  (HC-20), (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-SRC-1 (1135) (Upstate Biotechnology, Inc., Lake Placid, NY), anti-SRC-2 (ab9261), and anti-SRC-3 (ab2782), (Abcam, Cambridge, MA). DNA fragments were purified (QIAquick PCR Purification Kit; QIAGEN) and PCR amplified. The primers used for ChIP are listed in supplemental Table 2.

### Bioinformatics

To find putative ER target genes, the 192 sequences from the ChIP library were mapped to the human genome (HG 35.1

reference assembly) using BLAST with a threshold 1e-30. A set of 173 sequences that had significant hits was returned with four genes each: the nearest gene on each strand in each of the forward and reverse directions. Putative target genes were selected according to their positions relative to the hits. The computational programs MATCH (49) and Dragon ERE finder (50) were used to scan the 173 sequences for putative EREs, AP-1, SP1, foxA1, and NF $\kappa$ B. These two programs search for sites by scoring their similarity to experimentally verified EREs. When applying MATCH, two ERE position weight matrices, one from the TRANSFAC (51) database (matrix ID: V \$ER\_Q6), and the other one built from 25 EREs known in literature (52) were used. In these cases the threshold for declaring a putative ERE was set to minimize the sum of the false positives and false negatives. When applying the Dragon ERE finder, the default threshold for obtaining 0.83 sensitivity was used.

### Acknowledgments

We thank Pierre Chambon and Jan-Åke Gustafsson for providing plasmids, and Paul Webb for valuable comments on the manuscript.

Received July 9, 2007. Accepted October 19, 2007.

Address all correspondence and requests for reprints to: D.C.L.: University of California, San Francisco, MS 1258 P.O. Box 0556, San Francisco, California 94143-0556. E-mail: dale@leitmanlab.com.

This work was supported by grants from the National Institutes of Health (DK061966) and the American Cancer Society.

Disclosure Statement: The authors have nothing to disclose.

### REFERENCES

1. Writing Group for the Women's Health Initiative 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 288:321–333
2. MacGregor JI, Jordan VC 1998 Basic guide to the mechanisms of antiestrogen action. *Pharmacol Rev* 50: 151–196
3. Jordan VC 2004 Selective estrogen receptor modulation: concept and consequences in cancer. *Cancer Cell* 5:207–213
4. Cummings S, Eckert S, Krueger K, Grady D, Powles T, Cauley J, Norton L, Nickelsen T, Bjarnason N, Morrow M, Lippman ME, Black D, Glusman J, Costa A, Jordan V 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women. *JAMA* [Erratum (1999) 282: 2184] 281:2189–2197
5. Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant H, Christiansen C, Delmas P 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. *JAMA* 282:637–644
6. Christodoulakos GE, Botsis DS, Lambrinou IV, Pagianni VD, Panoulis CP, Creatsa MG, Alexandrou AP, Augoulea AD, Dendrinou SG, Creatsas GC 2006 A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. *Maturitas* 53:413–423
7. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L,

- Pajon Jr ER, Wade III JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N 2006 Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA* 295:2727–2741
8. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function *in vitro* reveals three distinct classes of antiestrogens. *Mol Endocrinol* 9:659–669
  9. Klein-Hitpass L, Schorpp M, Wagner U, Ryffel GU 1986 An estrogen-responsive element derived from the 5' flanking region of the *Xenopus* vitellogenin A2 gene functions in transfected human cells. *Cell* 46:1053–1061
  10. Webb P, Lopez GN, Uht RM, Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. *Mol Endocrinol* 9:443–456
  11. Safe S 2001 Transcriptional activation of genes by 17 $\beta$ -estradiol through estrogen receptor-Sp1 interactions. *Vitam Horm* 62:231–252
  12. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. *Cell* 103:843–852
  13. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F 2003 Estrogen receptor- $\alpha$  directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. *Cell* 115:751–763
  14. Smith CL, O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. *Endocr Rev* 25:45–71
  15. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. *Science* 295:2465–2468
  16. Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinney E, Katzenellenbogen BS, Stallcup MR, Kushner PJ 1998 Estrogen receptor activation function 1 works by binding p160 coactivator proteins. *Mol Endocrinol* 12:1605–1618
  17. Dutertre M, Smith CL 2003 Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor- $\alpha$ : regulation by phosphorylation sites in the A/B region depends on other receptor domains. *Mol Endocrinol* 17:1296–1314
  18. Kian Tee M, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ, Yamamoto KR, Leitman DC 2004 Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors  $\alpha$  and  $\beta$ . *Mol Biol Cell* 15:1262–1272
  19. Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR, Aldaz CM, Afshari CA, Walker CL 2003 Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. *Mol Cancer Res* 1:300–311
  20. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS 2003 Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. *Endocrinology* 144:4562–4574
  21. Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR, Katzenellenbogen BS 2004 Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER)  $\alpha$  or ER $\beta$  in human osteosarcoma cells: distinct and common target genes for these receptors. *Endocrinology* 145:3473–3486
  22. Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S, Spelsberg TC 2003 Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ER $\alpha$  or ER $\beta$ . *J Cell Biochem* 90:315–326
  23. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS 2004 Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. *Cancer Res* 64:1522–1533
  24. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoutte J, Shao W, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M 2005 Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. *Cell* 122:33–43
  25. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoutte J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M 2006 Genome-wide analysis of estrogen receptor binding sites. *Nat Genet* 38:1289–1297
  26. Lin Z, Reierstad S, Huang CC, Bulun SE 2007 Novel estrogen receptor- $\alpha$  binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. *Cancer Res* 67:5017–5024
  27. Lonard DM, O'Malley BW 2005 Expanding functional diversity of the coactivators. *Trends Biochem Sci* 30:126–132
  28. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature* 389:753–758
  29. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* 95:927–937
  30. Nettles KW, Greene GL 2005 Ligand control of coregulator recruitment to nuclear receptors. *Annu Rev Physiol* 67:309–333
  31. Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S, Spelsberg TC 2005 Estrogen receptor  $\alpha$  and  $\beta$  heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. *Mol Endocrinol* 19:1555–1568
  32. Choi I, Gudas LJ, Katzenellenbogen BS 2000 Regulation of keratin 19 gene expression by estrogen in human breast cancer cells and identification of the estrogen responsive gene region. *Mol Cell Endocrinol* 164:225–237
  33. Laganieri J, Deblois G, Giguere V 2005 Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor  $\alpha$ 1 gene in breast cancer cells. *Mol Endocrinol* 19:1584–1592
  34. Watanabe T, Inoue S, Hiroi H, Orimo A, Kawashima H, Muramatsu M 1998 Isolation of estrogen-responsive genes with a CpG island library. *Mol Cell Biol* 18:442–449
  35. Laganieri J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V 2005 From the cover: location analysis of estrogen receptor  $\alpha$  target promoters reveals that FOXA1 defines a domain of the estrogen response. *Proc Natl Acad Sci USA* 102:11651–11656
  36. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL 2002 Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. *Cancer Res* 62:3126–3131
  37. Jin VX, Leu YW, Liyanarachchi S, Sun H, Fan M, Nephew KP, Huang TH, Davuluri RV 2004 Identifying estrogen receptor  $\alpha$  target genes using integrated computational genomics and chromatin immunoprecipitation microarray. *Nucleic Acids Res* 32:6627–6635
  38. Bourdeau V, Deschenes J, Metivier R, Nagai Y, Nguyen D, Bretschneider N, Gannon F, White JH, Mader S 2004 Genome-wide identification of high-affinity estrogen response elements in human and mouse. *Mol Endocrinol* 18:1411–1427

39. So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR 2007 Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. *PLoS Genet* 3:e94
40. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors  $\alpha$  and  $\beta$ . *Endocrinology* 138: 863–870
41. Weatherman RV, Clegg NJ, Scanlan TS 2001 Differential SERM activation of the estrogen receptors (ER $\alpha$  and ER $\beta$ ) at AP-1 sites. *Chem Biol* 8:427–436
42. Levy N, Zhao X, Tang H, Jaffe RB, Speed TP, Leitman DC 2007 Multiple transcription factor elements collaborate with ER $\alpha$  to activate an inducible estrogen response element in the NKG2E gene. *Endocrinology* 148: 3449–3458
43. Levine M, Tjian R 2003 Transcription regulation and animal diversity. *Nature* 424:147–151
44. Li R, Knight JD, Jackson SP, Tjian R, Botchan MR 1991 Direct interaction between Sp1 and the BPV enhancer E2 protein mediates synergistic activation of transcription. *Cell* 65:493–505
45. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR 1990 Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. *Science* 249:1266–1272
46. Burakov D, Crofts LA, Chang CP, Freedman LP 2002 Reciprocal recruitment of DRIP/mediator and p160 co-activator complexes in vivo by estrogen receptor. *J Biol Chem* 277:14359–14362
47. Tzagarakis-Foster C, Geleziunas R, Lomri A, An J, Leitman DC 2002 Estradiol represses human T-cell leukemia virus type 1 Tax activation of tumor necrosis factor- $\alpha$  gene transcription. *J Biol Chem* 277:44772–44777
48. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC 2004 Estrogen receptor  $\beta$  inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. *Cancer Res* 64:423–428
49. Kel AE, Gossling E, Reuter I, Chermushkin E, Kel-Margoulis OV, Wingender E 2003 MATCH: a tool for searching transcription factor binding sites in DNA sequences. *Nucleic Acids Res* 31:3576–3579
50. Bajic VB, Tan SL, Chong A, Tang S, Strom A, Gustafsson JA, Lin CY, Liu ET 2003 Dragon ERE Finder version 2: a tool for accurate detection and analysis of estrogen response elements in vertebrate genomes. *Nucleic Acids Res* 31:3605–3607
51. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV, Kloos DU, Land S, Lewicki-Potapov B, Michael H, Munch R, Reuter I, Rotert S, Saxel H, Scheer M, Thiele S, Wingender E 2003 TRANSFAC: transcriptional regulation, from patterns to profiles. *Nucleic Acids Res* 31:374–378
52. O'Lone R, Frith MC, Karlsson EK, Hansen U 2004 Genomic targets of nuclear estrogen receptors. *Mol Endocrinol* 18:1859–1875

